Fluorescent Formazans and Tetrazolium Salts - Towards Fluorescent Cytotoxicity Assays by Ladyman, Melissa K. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescent Formazans and Tetrazolium Salts - Towards
Fluorescent Cytotoxicity Assays
Citation for published version:
Ladyman, MK, Walton, JGA, Lilienkampf, A & Bradley, M 2016, 'Fluorescent Formazans and Tetrazolium
Salts - Towards Fluorescent Cytotoxicity Assays' Combinatorial chemistry & high throughput screening, vol.
19, no. 5, pp. 384-391. DOI: 10.2174/1386207319666160408150913
Digital Object Identifier (DOI):
10.2174/1386207319666160408150913
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Early version, also known as pre-print
Published In:
Combinatorial chemistry & high throughput screening
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Send Orders for Reprints to reprints@benthamscience.ae 
 Journal Name, Year, Volume 1 
 XXX-XXX/15 $58.00+.00 © 2014 Bentham Science Publishers 
Fluorescent Formazans and Tetrazolium Salts  – Towards Fluorescent 
Cytotoxicity Assays 
Melissa K. Ladyman, Jeffrey G. A. Walton, Annamaria Lilienkampf,* Mark Bradley*  
School of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, David Brewster Road, EH9 3FJ, 
Edinburgh, UK  
Abstract: Formazan-based colorimetric cytotoxicity assays, such as the MTT assay, are typically used to assess cell 
viability with only metabolically active cells reducing tetrazolium salts into the formazans, which is then quantified by 
absorbance. Fluorescence offers several advantages compared to colorimetric assays and would enable techniques such as 
flow cytometry and confocal microscopy to be used for analysis. Here, fluorescent formazans 10, 11 and 12, and their 
corresponding tetrazolium salts 13, 16 and 24, respectively, were synthesised by incorporation of a known fluorophore 
backbone (coumarin, fluorescein and rhodol) with disruption of the conjugated system preventing or reducing 
fluorescence of the tetrazolium salts. The tetrazolium moiety was able to quench the fluorescence of the incorporated 
fluorescein and O-methyl rhodol, whereas with the coumarin-based tetrazolium salt the fluorescence was only quenched 
under acidic conditions.. These tetrazolium salts were successfully reduced to the fluorescent formazans with cells and 
offer a step forward in the development of fluorescent cytotoxicity assays. 
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1. INTRODUCTION 
 Formazans were first described at the end of the 19th 
century but were largely ignored until the 1940’s when their 
potential as localisation stains in living systems was reported 
[1,2]. Interest in formazans increased after the discovery that 
the addition of triphenyltetrazolium chloride 1 to cells 
resulted in reduction of the pale yellow 1 to the deeply 
coloured triphenylformazan 2 (Figure 1A) [3]. This 
discovery resulted in the development of the formazan-based 
colorimetric cytotoxicity assay (typically called an MTT 
assay) using 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) 3 with the dye only reduced by 
cells that are metabolically active to give 3-(4,5-
dimethylthiazoyl-2-yl)-2,5-diphenylformazan 4 (Figure 1A) 
[4]. The mechanism of MTT reduction is still debated, but it 
is clear that it is reduced intracellularly. MTT was originally 
thought to be up-taken by endocytosis and reduced in 
perinuclear vesicles, such as lysosomes and endosomes [5]; 
however, MTT has since been used to measure membrane 
potentials, which is only possible if the tetrazolium salt can 
permeate the cell membrane [6]. Inside cells, the tetrazolium 
salt 3 is reduced (in an NADH/NADPH dependent manner) 
to give the strongly coloured formazan 4, which is readily 
quantified by absorbance and can be used as a cellular 
viability marker [7]. However, the reduction product 4 is not 
soluble in aqueous media, requiring a solubilisation process, 
which complicates the assay and introduces error.  
 Sulphonated tetrazolium salts, including 2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide 5 and 3-(4-5-dimethylthiazoyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-tetrazolium salt 
6, were developed to increase the aqueous solubility of the 
formazans, eliminating the need for a solubilisation step in 
the assay (Figure 1B) [8]. However, their cellular uptake is 
limited and the reduction is not as efficient as for MTT 2 and 
requires the use of an intermediate electron acceptor (such as 
phenazine methosulfate) to promote reduction [9, 10]. Based 
on these, another class of water soluble tetrazolium salts 
(WSTs) was developed, including 4-(3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio)-1,3-benzene disulfonate salt 
(WST-1) 7 (Figure 1B) [11], and other WSTs similar to 7 
have become available for use in cytotoxicity assays. 
Although the tetrazolium salt is reduced to a highly water-
soluble formazan, the mechanism of reduction is 
significantly different to the reduction of MTT, with 
reduction by membrane-based enzymes at the cell surface. 
Additionally, these WSTs may be reduced by other species 
in the media such as glutathione [12]. 
 Fluorescence offers several advantages compared to 
colorimetric assays, such as sensitivity. A fluorescent 
cytotoxicity assay would enable techniques such as flow 
cytometry and confocal microscopy to be used for analysis. 
The most frequently used fluorescent assay is the Alamar 
blue (or resazurin) assay [13], which has been used to test for 
bacterial contamination in milk since the 1950’s. In the 
Alamar blue assay, resazurin is reduced by oxidoreductases 
to generate the strongly fluorescent resorufin  (λEx/λEm 
570/590 nm); however, resorufin can be further reduced to a 
non-fluorescent dihydroresorufin, which in cytotoxicity 
assays can significantly underestimate cell viability. Given 
the utility of the MTT assay and the benefits of fluorescence-
based detection it is surprising that there is not currently a 
fluorescent formazan-based cytotoxicity assay for 
mammalian cells. 3-Cyano-1,5-ditolyl tetrazolium chloride 8, 
which upon reduction gives a fluorescent formazan 9 
(λEx/λEm 488/630 nm) (Figure 1C), and has been used as a 
viability assay for anaerobic bacteria [14] but cannot be used 
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Figure 1. (A) Triphenyltetrazolium chloride 1 and MTT 3 are reduced in vitro to coloured formazans 2 and 4, respectively. (B) Tetrazolium salts 5, 6, and 7 are 
used in the 2nd generation cytotoxicity assays, which result in the formation of water-soluble formazans.  (C) Non-fluorescent 3-cyano-1,5-ditolyl tetrazolium 
chloride 8 is reduced by anaerobic bacteria into fluorescent 3-cyano-1,5-ditolylformazan 9 (λEx/λEm 488/630 nm) [14]. The two methyl groups in the phenyl rings 
of 9 are essential for the fluorescence as the structurally similar 3-cyano-1,5-diphenylformazan is non-fluorescent. 
with eukaryotic cells as it cannot cross the eukaryotic cell 
membrane [15]. Although 9 is commonly used as an 
indicator of bacterial viability, studies have raised questions 
about the accuracy of the assay as different species give 
different responses and 8 may also be reduced by chemical 
additives in the culture media [16, 17]. Here, we present the 
design and synthesis of fluorescent formazans and their 
corresponding tetrazolium salts. 
 
2. EXPERIMENTAL 
All chemicals were purchased from commercial suppliers 
and used as received. Microwave assisted heating was done 
in a Biotage Initiator at 2.45 GHz at a fixed temperature. 1H 
and 13C NMR spectroscopy were recorded on an automated 
Bruker AVA400 (400 and 100 MHz, respectively) or Bruker 
AVA500 (500 and 126 MHz, respectively) spectrometer and 
the chemical shifts are quoted in relative to the solvent. ESI-
MS analysis was recorded on an Agilent 1100 system with 
mass spectra acquired on a VG platform single Quadrupole 
MS-electrospray positive or negative mode. HRMS were 
acquired using a Bruker MicroToF II in positive or negative 
mode, or using a Finnigan MAT 900 XLP high-resolution 
double-focusing mass spectrometer. FT-IR spectra were 
recorded on a Bruker Tensor 27 with a golden gate accessory 
for solid samples. Melting points were measured on a 
Gallenkampf melting point apparatus. 
UV absorbance analysis was conducted on an Agilent 8453 
spectrophotometer using 100% solvent as blank. 
Fluorescence emission was measured using a Jobin Yvon 
SPEX Fluoro Max fluorometer with Data Max version 2.20 
software in EtOH unless otherwise indicated. Quantum 
yields were calculated by comparison to either fluorescein 
(in 0.1 M NaOH) or harmaline (0.005 M H2SO4) standard. 
Absorbance and fluorescence measurements for quantum 
yields (in EtOH) were acquired with Synergy plate reader 
loaded with Gen5 (1.1) software using Costar 96-well, flat-
bottomed clear plates (see ESI).  
 
2.1. Synthesis  
7-Amino-4-methylcoumarin diazonium (14)  
7-Amino-4-methyl coumarin (0.2 g, 1.0 mmol) was 
suspended in AcOH (10 mL) and cooled to 0 °C. Amberlyst 
A26 based nitrite resin [91] (0.7 g, 3.0 mmol) was added 
portion-wise over 20 min, followed by p-toluenesulfonic 
acid (0.6 g, 3.0 mmol). The mixture was warmed to room 
temperature and stirred for 1 h. The mixture was filtered and 
the resulting amber filtrate was poured into cold diethyl ether 
(100 mL) and the resulting precipitate was collected and 
washed with cold ether (30 mL) to give 14 as a beige solid 
(0.2 g, 64%). mp 135–140°C; IR νmax (cm-1) 2284 (N≡N), 
1728 (C=O); 1H NMR (d6-DMSO, 400 MHz) δ 8.77 (1H, d, 
J = 2.0 Hz), 8.61 (1H, dd, J = 8.8, 2.0 Hz), 8.29 (1H, d, J = 
8.7 Hz), 7.46 (2H, d, J = 8.0 Hz), 7.10 (2H, d, J = 7.9 Hz), 
6.88 (1H, d, J =1.4 Hz), 2.51 (3H, s), 2.29 (3H, s); 13C NMR 
(100 MHz, d6-DMSO) δ 157.7, 151.7, 151.2, 145.5, 137.5, 
129.5, 128.2, 128.0, 127.4, 125.4, 120.4, 120.2, 116.9, 22.7, 
17.9; MS (ESI) m/z 381.1 [M+Na]+ 
 
3-(7-Amino-4-methylcoumarin)-2,5-phenyl formazan (10)  
Benzaldehyde phenylhydrazone 15 (78 mg, 0.4 mmol) in 
DMF (0.5 mL) and pyridine (0.1 mL), was cooled to 0 °C, 
and 7-amino-4-methylcoumarin diazonium salt 14 (144 mg, 
0.4 mmol) in cold 2M HCl (0.2 mL) was added drop-wise. 
The mixture was stirred at room temperature for 16 h. Upon 
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completion, the solution was poured into water (5 mL) and 
conc. HCl was added until the solution was acidic (pH 1). 
The resulting precipitate was filtered, washed with water (10 
mL), and dried in vacuo. Purification by column 
chromatography (50% EtOAc in hexane) gave 10 as a dark 
purple powder (68 mg, 62%). mp 204–209 °C; IR νmax 
(cm−1) 3052 (NH), 1721 (C=O), 1607 (N=N), 1507 (C=N), 
1219 (CN); 1H NMR (500 MHz, CDCl3) δ 15.00 (1H, s), 
8.12 (2H, d, J = 7.4 Hz), 7.90 (2H, d, J = 7.5 Hz), 7.58−7.55 
(3H, m), 7.52−7.46 (4H, m), 7.39 (1H, t, J = 7.3 Hz), 7.33 
(1H, dd, J = 8.6, 2.0 Hz), 6.19 (1H, d, J = 1.1 Hz), 2.43 (3H, 
d, J = 1.1 Hz); 13C NMR (126 MHz, CDCl3) δ 161.0, 155.1, 
152.2, 151.3, 147.6, 142.1, 136.5, 131.3, 129.6, 128.5, 128.4, 
126.4, 125.8, 121.8, 116.3, 113.0, 112.3, 103.1, 18.7; HRMS 
(ESI) [M-H]- m/z calculated for C23H17O2N4 381.1352, 
obtained 381.0924; UV/VIS (EtOH) λmax 387 nm; λex/em 
370/468 nm; Φ 0.11. 
 
3-(7-amino-4-methylcoumarin)-2,5-phenyl tetrazolium 
bromide (13) 
Formazan 10 (60 mg, 0.16 mmol) was suspended in EtOAc 
(0.68 mL) and heated to 50 °C. To this N-bromosuccinimide 
(74 mg, 0.20 mmol) in EtOAc (0.48 mL) was added and the 
mixture was stirred at 50 °C for 12 hours. After cooling to 
room temperature, the cream precipitate was collected by 
filtration and dissolved in DCM (3 mL). The solution was 
washed with aqueous sodium tetrafluoroborate (5 mL), dried 
over Na2SO4, and evaporated in vacuo to give 13 as a white 
powder (42 mg, 69%). No purification was required. mp 
234−239 °C;; IR νmax (cm-1) 1721 (C=O), 1457 (C=N); 1H 
NMR (400 MHz, d6-DMSO) δ 8.18 (2H, d, J = 7.1 Hz), 8.01 
(1H, dd, J = 8.6, 2.0 Hz), 7.95 (2H, d, J = 7.7 Hz), 7.81 (1H, 
d, J = 2.0 Hz), 7.70 (1H, t, J = 8.6 Hz), 7.63 (1H, t, J = 7.6 
Hz), 7.60–7.54 (5H, m), 6.38 (1H, d, J = 1.2 Hz), 2.42 (3H, 
d, J = 1.1 Hz); 13C NMR (126 MHz, d6-DMSO) δ 161.2, 
155.3, 152.4, 151.5, 147.8, 142.4, 136.8, 130.9, 129.2 (2 ×), 
128.2 (2 ×), 128.0, 125.9 (2 ×), 125.4, 121.5 (2 ×), 116.6, 
112.60, 111.9, 102.7, 18.9; ESI-MS [M]+ m/z 381.1; HRMS 
(ES) [M]+ m/z calculated for C23H17O2N4+ 381.1352 
obtained 381.1069; UV/VIS (EtOH) λmax 297 nm; λex/em 
350/432 nm; Φ 0.10 (EtOH) and 0.04 (in acidic 
PBS/MeOH). 
 
3-(Spiro[isobenzofuran-1(3H),9'- [9H] xanthen] -3-one,3'-
hydroxy-6'-phenyl-4,5-phenylformazan (11)   
Sodium nitrite (41 mg, 0.58 mmol) was added to 11 (185 
mg, 0.45 mmol) in 2M HCl (3 mL) at 0 °C and stirred for 90 
minutes. This solution was added drop-wise to a solution of 
diphenylhydrazone 15 (96 mg, 0.9 mmol) in DMF (1.2 mL) 
and pyridine (0.6 mL) at 0 °C. The reaction was stirred at 
room temperature for 22 hours. The reaction mixture was 
poured into water (10 mL) and acidified with 2M HCl to pH 
1, the precipitate was collected by filtration, and dried at 
40 °C in a vacuum oven for 24 hours. Purification by column 
chromatography (30% EtOAc in hexane) gave a 16 as dark 
red powder (104 mg, 38%). mp171−175 °C; IR νmax (cm-1) 
3373 (OH), 3032 (NH), 1728 (C=O); 1H NMR; (500 MHz, 
DMSO) δ 14.11 (1H, s), 10.10 (1H, s), 8.04 (1H, d, J = 7.6 
Hz), 7.99 (2H, d, J = 7.2 Hz), 7.93−7.88 (6H, m), 7.82 (1H, 
dt, J = 7.5, 1.0 Hz), 7.75 (2H, dd, J = 8.1, 4.6 Hz), 
7.56−7.53 (2H, m), 7.51−7.47 (3H, m), 7.39 (2H, d, J = 7.3 
Hz), 7.34 (1H, d, J = 7.6 Hz), 6.85 (1H, d, J = 8.3 Hz), 6.75 
(1H, d, J = 2.3 Hz), 6.64 (1H, d, J = 8.7 Hz), 6.59 (1H, dd, J 
= 8.7, 2.3 Hz); 13C NMR (126 MHz, d6-DMSO) δ 169.1, 
152.4, 151.7, 151.0, 148.3,146.9, 142.3, 141.9, 136.4, 135.7, 
135.6, 130.2, 129.7 (2 ×), 129.4, 128.8, 128.7 (2 ×), 128.6, 
128.2 (2 ×), 128.1, 126.7 (2 ×), 125.7, 124.7, 124.0, 122.1, 
121.0, 120.0 (2 ×), 119.2 (2 ×), 117.7, 114.3, 112.8, 109.1, 
102.2, 91.7; HRMS (ESI) [M+H]+ m/z calculated for 
C39H27O4N4 m/z 615.2023 obtained 615.2024; UV/VIS 
(EtOH) λmax 300, 500 nm; λex/em 370/445 nm; Φ 0.19. 
 
3-(Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,3'-
hydroxy-6'-phenyl-4,5-phenyltetrazolium bromide (16) 
Fluorescein formazan 16 (11.3 mg, 0.02 mmol) was 
suspended in EtOAc (0.3 mL) and heated to 50 °C. N-
bromosuccinimide (10 mg, 0.05 mmol) in EtOAc (0.3 mL) 
was added, and the mixture stirred at 50 °C for 12 hours. The 
precipitate was collected by filtration to give 16 (9.7 mg, 
86%). No purification was required. mp 171−175 °C; IR 
νmax (cm-1) 3359 (OH), 3034 (CH), 1758 (C=O), 1596 
(C=N); 1H NMR (400 MHz, MeOD) δ 8.39 (2H, d, J = 7.1 
Hz′), 8.10 (1H, d, J = 7.3 Hz ), 8.05 (2H, d, J = 8.6 Hz), 
7.88–7.87 (3H, m), 7.85–7.81 (5H, m), 7.77 (2H, d, J = 7.3 
Hz), 7.76–7.72 (5H, m), 7.51 (1H, d, J = 8.6 Hz), 7.30 (1H, 
d, J J = 8.0 Hz), 6.98 (1H, d, J = 8.0 Hz), 6.91 (1H, s); 13C 
NMR (126 MHz, MeOD) δ 161.3, 160.8, 157.9, 156.5, 
151.8, 151.5, 145.9, 145.2, 145.1, 141.0, 139.9, 139.8 (2 ×), 
138.6, 138.0, 137.9 (2 ×), 137.8, 137.5, 137.5 (2 ×), 135.9 (2 
×), 134.3, 133.7, 131.7, 129.2 (2 ×), 129.1, 128.5, 128.4 (2 
×), 128.3, 127.3, 123.9, 123.8, 122.2, 118.9, 118.8; ESI-MS 
m/z 613.3 [M]+; UV/VIS (EtOH) λmax 300 nm; λex/em 
370/432; Φ 0.01. 
 
1-(O-Methylrhodol)-3,5-diphenylformazan (12) 
Sodium nitrite (12 mg, 0.17 mmol) in water (300 µL) was 
added to O-methylrhodol 22 (50 mg, 0.15 mmol) in 2M HCl 
(0.75 mL) at 0 °C and stirred for 60 minutes. This solution 
was added to a solution of diphenylhydrazone 15 (30 mg, 
0.15 mmol) in cold DMF (1.75 mL) and pyridine (0.35 mL), 
and the reaction brought to room temperature. The reaction 
was stirred for 22 hours and then poured into water (10 mL). 
2M HCl was added until the solution became acidic (pH 1), 
the resultant crystals were collected by filtration and washed 
with water (20 mL). The solid was dried in a vacuum oven at 
40 °C to give dark red crystals (20 mg, 25%). No 
purification required. mp 201–204 °C; IR νmax (cm-1) 3061 
(NH), 1760 (C=O), 1614 (C=N), 1505 (NH), 1218 (CN); 1H 
NMR (500 MHz, CDCl3) δ 15.15 (1H, s,), 8.16 (2H, d, J = 
7.3 Hz), 8.07 (1H, d, J = 7.6 Hz), 7.86 (2H, d, J = 7.6 Hz), 
7.71 (1H, t, J = 6.5), 7.66 (1H, t, J = 7.4 Hz ′), 7.59–7.52 
(3H, m), 7.51–7.43 (3H, m), 7.41 (1H, t, J = 7.3 Hz), 7.22 
(1H, d, J = 7.5 Hz), 7.12 (1H, dd, J = 8.5, 1.9 Hz), 6.86–
6.79 (2H, m), 6.73 (1H, d, J = 8.8 Hz), 6.65 (1H, dd, J = 8.8, 
2.4 Hz), 3.85 (3H, s); 13C NMR (126 MHz, CDCl3) δ 
169.5,161.4, 153.2, 152.5, 152.4, 150.5, 147.1, 141.6, 136.9, 
135.1, 130.3, 129.8, 129.5 (2 ×), 129.2, 129.0, 128.4 (2 ×), 
128.0, 126.6, 126.1 (2 ×), 125.1, 123.9, 121.1 (2 ×), 115.2, 
112.7, 111.8, 111.0, 103.8, 100.9, 83.0, 55.6; HRMS (ES) 
m/z [M+H]+ calculated for C34H25N4O4 553.1870 obtained 
553.1726; UV/VIS (EtOH) λmax 298 & 483 nm;; λex/em 
350/428 nm; Φ 0.18. 
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1-(O-Methylrhodol)-3,5-diphenyl tetrazolium salt (24) 
Formazan 12 (20 mg, 0.03 mmol) was suspended in EtOAc 
(0.6 mL) and warmed to 50 °C. To this N-bromosuccinimide 
(16 mg, 0.09 mmol, 2.5 eq.) in EtOAc (0.4 mL) was added, 
and the mixture was stirred at 50oC for 16 hours. The 
precipitate was collected by filtration, to afford a cream 
powder (15 mg, 83%). No purification was required. mp 
142−147 °C; IR νmax (cm-1) 1695 (C=O), 1102 (COC); 1H 
NMR (500 MHz, CDCl3) δ 8.17 (2H, d, J = 7.4 Hz), 8.04 
(1H, d, J = 7.6 Hz), 7.89 (1H, d, J = 2.2 Hz), 7.82 (2H, d, J 
= 7.9 Hz), 7.75 (1H, t, J = 7.4 Hz) 7.67−7.64 (2H, m), 7.61–
7.49 (5H, m), 7.33 (1H, dd, J = 8.6, 2.1 Hz), 7.18 (1H, d, J = 
7.6 Hz), 6.92 (1H, d, J = 8.6 Hz, H8), 6.79 (1H, d, J = 1.9 
Hz), 6.74–6.66 (2H, m), 3.85 (3H, d, J = 7.2 Hz); 13C NMR 
(126 MHz, CDCl3) δ 176.9, 168.8, 166.0, 161.8, 152.1, 
151.7, 151.6, 135.8, 134.1, 134.0, 133.2, 133.0, 130.5 (2 ×), 
130.1, 129.4 (2 ×), 128.8, 128.0 (2 ×), 126.2 (2 ×), 125.8, 
125.4, 124.9, 124.0, 122.9, 120.4, 116.0, 113.1, 109.8, 101.0, 
81.1, 55.7; HRMS (ES) m/z [M]+ calculated for C34H23N4O4+ 
555.1714 obtained 555.3324. 
 
2.1. Reduction of tetrazolium salt in cells   
HEK293T cells were cultured in T75 culture flasks in 
Dulbecco's modified Eagle's medium (DMEM), 
supplemented with 10 % FBS, 4 mM glutamine, and 100 
units/mL of penicillin/streptomycin, and grown to 50–60% 
confluence. Tetrazolium salts 13, 16, or 24 (0.5 mM in 1 mL 
DMSO) were added to phenol red free DMEM media (10 
mL) to give a final concentration of 50 µM. DMEM cell 
media was removed and replaced with DMEM with 
tetrazolium salts and the cells were incubated at 37 °C for 24 
hours. The media was removed and the cells washed with 
PBS three times. The PBS and media were combined and 
centrifuged (1200 rpm) for 15 minutes. The supernatant was 
removed leaving the formazan residue, which was dried at 
40 °C in a vacuum oven, and then dissolved in EtOH (5 mL) 
and fluorescence was recorded. The samples were also 
analysed by mass spectrometry to confirm presence of the 
formazans 10–12. 
 
3. RESULTS AND DISCUSSION 
 It is difficult to predict whether or not a molecule will be 
fluorescent; however, planarity and extended conjugation are 
common features in fluorescent molecules [18], but not all 
highly conjugated molecules are fluorescent (for example 
MTT 3 and the corresponding formazan 4 are not 
fluorescent). Here, we targeted fluorescent formazans using 
three known fluorescent cores (coumarin, fluorescein and 
rhodol). The hypothesis was that a “switch-on” fluorescent 
assay, similar to the MTT assay, would be possible by 
introducing a fluorophore into the formazan, with disruption 
of the conjugated system preventing or reducing 
fluorescence, i.e., the positive charge of the corresponding 
tetrazolium salt (Figure 2).  
 
Figure 2. Design of fluorescent formazans 10, 11 and 12, incorporating 
coumarin, fluorescein or rhodol-based fluorophores, for cytotoxicity assays. 
The fluorescence was postulated to be quenched (“turned-off”) in the 
corresponding tetrazolium salts, proving a “switch-on” mechanism for the 
fluorescence detection upon cellular reduction.  
 Scheme 1. (a) Amberlyst A26 based nitrite resin, AcOH, p-TsOH, 0 °C to rt, 
1 h, (64%) (b) 2M HCl, NaNO2, benzaldehyde phenylhydrazone 15, 
pyridine, DMF, 4 h (62%); (c) NBS, EtOAc, 50 °C, 20 h (69%). 
 
3.1. Synthesis of fluorophore-based formazans and 
tetrazolium salts 
The first target molecule was 10, which can be considered 
to be a formazan attached to the fluorophore 7-amino-4-
methyl coumarin (AMC), which has an available aniline 
group for incorporation into the formazan core. Coumarins 
are of particular interest as they are known to have high 
quantum yields and retain high fluorescence even following 
large structural changes [19, 20]. The corresponding 
coumarin-based tetrazolium salt 13 was synthesised in three 
steps (Scheme 1). 7-AMC  [20] was diazotised using a solid-
supported nitrite resin [21] and 14 was isolated as the p-
toluenesulfonic acid salt. Benzaldehyde phenylhydrazone 15 
[22] was added to the diazonium salt 14 in 2M HCl to give 
the coumarin–formazan 10 in 62% yield. Oxidition with N-
bromosuccinimide (NBS) gave the corresponding 
tetrazolium 13 in 69% yield. 
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Scheme 2. Synthesis of fluorescein–formazan 11 and the corresponding fluorescein–tetrazolium salt 16. a) PhN(OTf)2, K2CO3, DMF, 20 min, mw 80 °C (48%); 
b) 4-aminophenyl boronic acid pinacolester, Pd(OAc)2, PPh3, Na2CO3, toluene/EtOH (1:1), 80 °C, 22 h (71%), (c) 2M HCl, NaNO2, H2O, 0 °C, 90 min; d) 
benzaldehyde phenylhydrazone 15, pyridine, DMF, 0 °C to rt, 18 h (38%); (e) NBS, EtOAc, 50 °C,  24 h (86%). 
 
Scheme 3. Synthesis of 12 and the corresponding tetrazolium salt 24. a) NaOH, MeOH, 2 h; b) MeI, DMF, 24 h; c) LiOH, MeOH, 100 °C, 24 h (71%); d) 
PhN(OTf)2, DIPEA, DMF, 2 h (78%); e) t-butyl carbamate, Pd(dbba)3, xantphos, CsCO3, dioxane, N2 atm, 18 h (75%); f) 20%TFA in DCM, 2 h (95%); g) 
NaNO2, HCl, 0 °C, 1 h; h) 15, pyridine, DMF, 0 °C to rt, 18 h (25%); i) NBS, EtOAc, 50 °C, 16 h (83%). 
The “fluorescein-based” tetrazolium salt 16 was 
synthesised in five steps from fluorescein. Fluorescein 
monotriflate 17 was synthesised by microwave heating 
fluorescein and N-phenyl-bis(trifluoromethanesulfonimide) 
(PhN(OTf)2) in the presence of K2CO3 [23], followed by a 
Suzuki coupling with 4-aminophenyl boronic acid pinacol 
ester under thermal conditions to give 18 in 71% yield 
(Scheme 2) [24]. Diazotisation of 18 and subsequent 
treatment with benzaldehyde phenylhydrazone 15 afforded 
the desired fluorescein–formazan 11 in 29% yield, with 
oxidation using NBS giving the tetrazolium salt 16 in 86% 
yield. 
To allow regioselective incorporation of the formazan 
moiety into a rhodol-based fluorophore (compound 12), 
mono O-methyl fluorescein 19 was synthesised [25]. 
Fluorescein was first treated with methyl iodide (with 
concomitant methyl ether and methyl ester formation) and 
subsequent hydrolysis with LiOH gave 19 in 71% yield. 
Conversion of the phenol moiety in 19 to the corresponding 
aniline 22 was achieved by the method of Grimm [26], i.e., 
triflation (compound 20), followed by Buchwald-Hartwig 
amination with tert-butyl carbamate (compound 21) and 
deprotection to afford O-methyl rhodol 22 as a TFA salt in 
56% overall yield over three steps (Scheme 3). O-Methyl 
rhodol 22 was treated with sodium nitrite, to generate the 
diazonium salt 23, which was then treated with 
diphenylhydrazone 15 to furnish the desired formazan 12 in 
moderate 25% yield (Scheme 3). NBS oxidation gave the 
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corresponding tetrazolium salt 24, which precipitated from 
the reaction mixture and was isolated by filtration in 83% 
yield. 
 
3.2. Optical properties of the tetrazolium salts and 
formazans 
 The optical properties of the fluorophore-based 
formazans and their corresponding tetrazolium salts were 
analysed and compared to the optical properties of the 
“parent fluorophores” (Table 1). The formazans 10, 11 and 
12 all showed fluorescence emission between 420 and 470 
nm (in EtOH) (Figure 3). The emission wavelength of the 
formazans was not dependent on the emission wavelength of 
the parent fluorophore.  
 
Table 1. Optical properties of the synthesised formazans and 
tetrazolium salts, and their “parent” fluorophores (in EtOH 
unless otherwise stated).  
Compound λEx (nm) λEm (nm) Φ 
AMC  350 426 0.78 
10 370 468 0.11 
13 350 432 0.10 
13 pH 4[a] 390 432 0.04 
18 480 520 0.26 
11 370 445 0.19 
16 370 434[b] –[c] 
22 428 523 0.74 
12 350 428 0.18 
24 350 n/f[d] – 
[a] recorded in acidified PBS/MeOH [b] weakly fluorescent, 4.8-fold 
difference in emission intensity compared to 11 [c] could not be determined 
[d] non-fluorescent. 
 Coumarin-based formazan 10 showed a 42 nm red shift 
compared to AMC, possibly due to the increased conjugation 
gained from the formazan structure; however, the quantum 
yield of 10 was lower than that of reported for AMC (Φ 0.11 
versus 0.78) [27]. The coumarin-based tetrazolium salt 13 
remained fluorescent in EtOH (λEm 432 nm, Φ 0.10) with a 
36 nm blue-shift in fluorescence compared to 10 (4-fold 
difference between the emission intensities (λEx 350 nm) of 
13 and 10) (ESI, Figure S1). However, under aqueous acidic 
conditions (1:1 MeOH/PBS with 1% HCl), 13 was almost 
non-fluorescent whereas formazan 10 retained its fluorescent 
properties (60-fold difference in emission intensities) (Figure 
4A). The difference in fluorescent intensity between 13 and 
the reduced form 10 could thus be exploited in a cytotoxicity 
assay where the tetrazolium salt is reduced to a fluorescent 
formazan and extracted in acidic PBS/MeOH (similar to that 
used for the MTT assay). 
 Aniline modified fluorescein 18 had a fluorescence 
emission maximum at 520 nm (λEm 480 nm) and a quantum 
yield of 0.26. When this moiety was incorporated into  
Figure 3. Comparison of fluorescence emission of formazans 10 (λex/em 
370/468 nm), 11 (λex/em 370/445 nm), and 12 (λex/em 350/428 nm) in EtOH 
(recorded at 1 µM). 
Figure 4. (A) Fluorescence emission of coumarin-based formazan 10 (λex/λem 
370/468 nm) and the corresponding tetrazolium salt 13 (λex 390 nm) in acidic 
PBS–MeOH (1:1). (B) Fluorescence emission of fluorescein–formazan 11 
emission (λex/λem 370/445 nm) and its tetrazolium salt 16 emission (λex/λem 
370/434 nm in EtOH); (C) Fluorescence emission of O-methylrholdol-based 
formazan 12 emission (λex/λem 350/428 nm) compared to its tetrazolium salt 
24 (λex 350 nm) recorded in EtOH.  
 
formazan 11, the emission was blue-shifted by 75 nm to 445 
nm (Φ 0.19) (ESI, Figure S2). The corresponding 
tetrazolium salt 16 was considerably less fluorescent than the 
formazan counterpart (Figure 4B). Similarly with O-methyl 
rhodol-based formazan 12 (λEx/λEm 370/427 nm, Φ 0.18) the 
emission was blue-shifted by 96 nm compared to parent 
fluorohore O-methyl rhodol 22 (λEm 523 nm) (ESI, Figure 
S3). The tetrazolium salt 24 was non-fluorescent (λEx 350 
nm) showing that as postulated the positive charge of the 
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tetrazolium salt is able to quench the fluorescence (Figure 
4C).  
 
3.3. Cell-based fluorescence analysis  
Tetrazolium salts 13, 16 and 24 (50 µM) were incubated with 
HeLa cells for 20 hours to allow the reduction to the 
formazans 10, 11 and 12, respectively. Formation of non-
soluble crystals was observed on the surface of the cells 
(Figure 5A–B). The formazan crystals were isolated, 
solubilised in EtOH, and the fluorescence was measured 
with the expected emission observed with all the samples 
(Figure 5C, ESI Figure S4). For the coumarin-based 
tetrazolium salt 13 the cell-based reduction into 10 was also 
confirmed by mass spectrometry of both the supernatant and 
cell lysate, which confirmed that 13 had been taken up by the 
cells. Coumarin-based 10 and 13 did not show notable 
cytotoxicity in a MTT assay at 100 µM, whereas with 
formazans 11 and 12 were non-cytotoxic up to 10 µM 
(tetrazolium salts 16 and 24 were not toxic at 50 µM) (ESI 
Figure S5). 
Figure 5. A) HeLa cells immediately after the addition of tetrazolium salt 10 
(10 µM). B) Cells following 28 hours incubation showing dark formazan 13 
crystals (× 40 magnification). C) Fluorescent emission of recovered 10 after 
24 hour incubation of 13 (50 µM) with HeLa cells. Supernatant was removed 
and the formazan crystals were collected by centrifugation and dried. 
Fluorescence was measured in EtOH. 
 
CONCLUSION 
 The fluorescent formazans 10, 11 and 12, and their 
corresponding tetrazolium salts 13, 16 and 24, respectively, 
were synthesised by incorporation of a known fluorophore. The 
large structural changes to the core structure did not affect the in 
vitro activity of the tetrazolium salts, which were successfully 
reduced to the fluorescent formazans with cells. The emission 
wavelengths of the fluorophore conjugated formazans were not 
directly dependent on the parent fluorophores, i.e., the 
fluorescence of 10 was red shifted compared to AMC whereas 
both fluorescein-based 11 and O-methyl rhodol-based 12 were 
blue shifted to the green region and were lower than the 
emission of 10. The tetrazolium moiety was able to quench the 
fluorescence of incorporated fluorescein and O-methyl rhodol 
(compounds 16 and 24, respectively), whereas with the 
coumarin-based 13 the fluorescence was only quenched in 
acidic medium, which is typically used in MTT assay. These 
new tetrazolium salts and their corresponding formazans offer a 
step forward in the development of “turn on” fluorescent 
cytotoxicity assays. 
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SUPPLEMENTARY MATERIAL 
Figure S1. Fluorescence emission of coumarin-based 10 and 
13. 
Figure S2.  Fluorescence emission of 11 compared to 18. 
Figure S3. Fluorescence emission of O-methylrhodol 22 and 
12. 
Figure S4. Fluorescence of recovered 11 and 12 from HeLa 
cells. 
Figure S5.  MTT cytotoxicity assays 
Equation 1. Calculation of quantum yields. 
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